Estimated costs of production and potential prices for the WHO Essential Medicines List.

about

Estimated costs of production and potential prices for the WHO Essential Medicines List.

Item

http://www.wikidata.org/entity/Q53699577

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@en

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@nl

type

Item

label

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@en

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@nl

prefLabel

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@en

Estimated costs of production and potential prices for the WHO Essential Medicines List.

@nl

P1476

Estimated costs of production and potential prices for the WHO Essential Medicines List

@en

P2093

Andrew M Hill

http://www.w3.org/2001/XMLSchema#string

Melissa J Barber

http://www.w3.org/2001/XMLSchema#string

P2860

Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

25 years of the WHO essential medicines lists: progress and challenges.

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Essential medicines for universal health coverage.

Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.

P304

e000571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJGH-2017-000571

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dzintars Gotham

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29564159

http://www.w3.org/2001/XMLSchema#string

P921

Alþjóðaheilbrigðismálastofnunin

P932

5859811

http://www.w3.org/2001/XMLSchema#string